REGENXBIO to Receive $80.0 Million Milestone Payment from Novartis AG
- Milestone payment based on achievement of $1.0 billion in cumulative net sales of Zolgensma®
- Zolgensma is the first gene therapy based on REGENXBIO’s NAV® Technology Platform approved by the FDA and other regulatory authorities